

PreveCeutical Medical Inc.

12:25 01 Oct 2020

PreveCeutical Medical names former Johnson & Johnson executive as consultant as it enters commercialization phase

PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) (FRA:18H), the health sciences group, has named former executive at multinational giant Johnson & Johnson (NYSE:JNJ) Dr. Ajit Shetty as an advisor and consultant to the company.

"With the company actively working on development, clinical trials, and commercialization of its products, Dr. Shetty's guidance will be very critical in its success," said Stephen Van Deventer, PreveCeutical's chief executive in a brief statement.

READ: PreveCeutical pleased with rodent model of opioid substitute pain-reliever

"We are very excited and fortunate to have Dr. Shetty work with us."

Illustrious Dr Shetty brings extensive pharmaceutical experience leading commercial and supply chain operations and was 36 years at Johnson & Johnson (J&J) in a wide range of global roles.

"From 2007 to 2012, he served as corporate vice president, enterprise supply chain reporting to the CEO and was responsible for the transformation and optimization of J&J's supply chain. In addition, from 2004 to 2012, he served as chairman of Janssen Pharmaceutical," noted Preveceutical.

He was elected "Manager of the Year 2004" by the magazine Trends, and Kanaal Z and was awarded the Right Honourable Sir and Title of Baron by King Albert II of Belgium in 2008 and the Life-Time Achievement Award by India in 2010.

Shares in Canada were unchanged at C\$0.040.

Contact the author at giles@proactiveinvestors.com

Price: 0.035**Market Cap:** \$17.22 m

1 Year Share Price Graph



Share Information

Code: PREV**Listing:** CSE**52 week**

High	Low
0.1	0.01

Sector: Medical technology & services**Website:** preveceutical.com

Company Synopsis:

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilising organic and nature identical products.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).